TABLE 3.

Associations between tagging SNPs of CDHR3 and clinical outcomes of our children under the additive model

	Odds ratio (95% CI), P value
SNP (A/a)	Lower RTI	RV-C-associated lower RTI	Wheeze	RV-C-associated wheeze	Asthma exacerbation (AE)	RV-C-associated AE	Oxygen supplement	Systemic corticosteroid
rs3887998	1.01 (0.82–1.24), 0.931	1.09 (0.87–1.36), 0.453	1.00 (0.81–1.23), 0.981	1.04 (0.83–1.30), 0.761	0.98 (0.76–1.25), 0.845	1.03 (0.78–1.35), 0.845	0.79 (0.56–1.12), 0.181	0.97 (0.73–1.29), 0.843
rs140154310	2.06 (0.97–4.37), 0.059	2.55 (1.24–5.24), 0.011 a	2.38 (1.12–5.04), 0.024	2.71 (1.32–5.58), 0.007	1.88 (0.88–4.03), 0.106	1.78 (0.78–4.07), 0.174	0.86 (0.26–2.885), 0.805	1.72 (0.72–4.13), 0.225
rs73195657	1.45 (0.97–2.17), 0.074	1.47 (0.97–2.23), 0.071	1.42 (0.95–2.13), 0.087	1.36 (0.89–2.08), 0.151	1.11 (0.69–1.78), 0.663	0.96 (0.56–1.66), 0.895	1.19 (0.65–2.18), 0.576	1.39 (0.83–2.32), 0.218
rs146004234	0.87 (0.50–1.50), 0.608	1.00 (0.56–1.81), 0.989	0.94 (0.54–1.63), 0.827	1.06 (0.59–1.92), 0.836	0.88 (0.46–1.70), 0.712	1.13 (0.57–2.23), 0.721	0.87 (0.37–2.04), 0.742	1.04 (0.51–2.12), 0.918
rs4730125	0.93 (0.76–1.14), 0.495	0.96 (0.77–1.19), 0.680	0.96 (0.78–1.18), 0.696	0.95 (0.76–1.18), 0.630	0.78 (0.61–1.00), 0.054	0.81 (0.62–1.07), 0.135	0.92 (0.67–1.26), 0.596	0.80 (0.60–1.07), 0.131
rs6967330	1.20 (0.89–1.62), 0.230	1.35 (0.98–1.85), 0.063	1.22 (0.90–1.65), 0.194	1.34 (0.97–1.84), 0.073	1.08 (0.75–1.54), 0.688	1.29 (0.88–1.89), 0.193	1.32 (0.86–2.05), 0.208	1.45 (0.99–2.12), 0.057
rs73195665	1.17 (0.78–1.75), 0.452	1.18 (0.77–1.80), 0.450	1.25 (0.84–1.87), 0.279	1.20 (0.78–1.84), 0.401	1.14 (0.72–1.81), 0.577	1.20 (0.72–1.99), 0.489	0.93 (0.49–1.77), 0.821	1.69 (1.04–2.74), 0.035
rs408223	0.93 (0.69–1.25), 0.634	0.67 (0.47–0.95), 0.025	0.91 (0.67–1.23), 0.537	0.72 (0.51–1.02), 0.065	1.15 (0.81–1.62), 0.438	0.93 (0.63–1.39), 0.736	1.25 (0.80–1.95), 0.335	1.13 (0.76–1.70), 0.544

^a Statistically significant results are highlighted in bold.